Peptides DB
Research-centric peptide and protocol reference hub
Study 25 of 29SS-31 literaturebiorxiv-preprint · Observational2026

Epidemiology of frailty, multimorbidity, and disability: a cross-sectional study of mid-aged and older adults in The Gambia, Zimbabwe and South Africa

A third of mid-aged to older adults in this study had multimorbidity, and nearly a quarter were disabled, highlighting the need for patient-centered interventions.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the ss-31 corpus
2
Preclinical
20
Observational · this one
0
Open-label
3
Randomised
4
Reviews

Summary and findings

This study quantified the overlap between multimorbidity, frailty, and disability in adults aged ≥ 40 years across five settings in Africa. The study found that 36.3% of participants were multimorbid, 14.1% were frail, and 22.9% were disabled. The overall mean HRQoL utility score was 0.829 ± 0.107.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Overall mean HRQoL utility score was 0.829 ± 0.107.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p>Background Multimorbidity, frailty and disability risk are increasing with longevity across Africa. We aimed to quantify the overlap between multimorbidity, frailty, and disability; assess associations with health-related quality of life (HRQoL); and between individual long-term conditions (LTCs) and frailty and disability. Methods This population-based cross-sectional study recruited adults aged ≥ 40 years in five settings: rural(n = 1052) and urban Gambia(n = 1218), rural(n = 948) and urban South Africa (SA) (n = 968), and urban Zimbabwe(n = 1110). Researcher-administered questionnaires and assessments determined LTCs by self-reported diagnosis, medication use, blood pressure, glucose and HIV testing. Multimorbidity was defined as ≥ 2 LTCs, disability by Washington Group questionnaire, frailty using five Fried criteria (≥ 3 frail, 1–2 pre-frail, 0 robust), and HRQoL using EuroQol-5 Dimension 5-Level. A minimally important difference [MID] was considered half a standard deviation[SD]. Results Of 5,296 adults (mean age 61.0 [SD:12.9] years, 53.3% (n = 2823) female), 1924 (36.3%) were multimorbid, 741 (14.1%) frail, 3199 (60.7%) prefrail, and 1211 (22.9%) disabled. Overall, 202(3.8%) had the triad of multimorbidity, frailty, and disability (range: 10.6% urban SA, to 5.5% rural Gambia). Mood disorders (odds ratio [OR] 7.16 [95%CI: 4.16;12.33]), severe mental illness (4.66 [2.71;8.00]), and chronic kidney disease (4.25 [1.62;11.10]) were associated with frailty, whilst mood disorders (3.19 [2.48;4.09]), arthritis (2.78 [1.54;4.94]), and cardiac disease (2.50 [1.66;3.56]) were associated with disability. Age-adjustment strengthened associations, and revealed disability associations with epilepsy, HIV, and prior tuberculosis. The overall mean ± SD HRQoL utility score was 0.829 ± 0.107 (MID = 0.054). In younger adults (40–54 years), a HRQoL MID was observed in females with multimorbidity, pre-frailty and disability, and in men with frailty and disability (+/- multimorbidity). In older ages (≥ 55 years), a HRQoL MID was reached in females and males with pre-frailty or frailty and disability (+/- multimorbidity). Conclusions A third of mid-age to older adults were living with multimorbidity, three-quarters with frailty or pre-frailty and a quarter with disability. Patient-centred interventions, rather than disease-based approaches, should be evaluated and may improve functional and health outcomes and quality of life in people living with multimorbidity, frailty, and disability.</p>

Background

The study likely addresses the prevalence and characteristics of frailty, multimorbidity, and disability among mid-aged and older adults in The Gambia, Zimbabwe, and South Africa. Understanding these factors is crucial for public health planning and resource allocation in these regions.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the SS-31 corpus

DStatistical analysis plan for the ‘Pharyngeal electrical stimulation for acute stroke dysphagia trial’ (PhEAST) (ISRCTN98886991)biorxiv-preprint · 2026 · Not reported in abstract.reviewAUse of nicotine replacement therapy to reduce children’s exposure to second-hand smoke in the home: Findings of a pilot randomised controlled trial conducted in Scotlandbiorxiv-preprint · 2026 · Median PM 2.5 concentrations reduced in the intervention group by -36μg/m 3.HumanACardiovascular and autonomic responses to transcutaneous spinal cord stimulation combined with activity-based therapy after chronic spinal cord injury: An exploratory study from the MACHINE trialbiorxiv-preprint · 2026 · Not reported in abstract.HumanBOptimising the prevention, detection and management of diabetes distress in adults with type 1 diabetes: Feasibility study protocol (D-stress feasibility study)biorxiv-preprint · 2026 · Not reported in abstract.HumanDParent-mediated interventions versus usual care in children with autism: A systematic review with meta-analysis and Trial Sequential Analysisbiorxiv-preprint · 2026 · MD = −0.88; 95% confidence interval −2.92 to 1.15; p = 0.05, 4 trials, N = 353, low certainty.reviewBClassical driver mutations are not associated with metachronous lesion risk in patients undergoing post-polypectomy surveillance following removal of conventional adenomas in a bowel screening settingbiorxiv-preprint · 2026 · Mutation frequency in index adenomas was not associated with metachronous lesions (p=0.901).Human